Epstein-Barr virus is associated with a variety of human malignancies. These malignancies harbor latent virus with limited expression of virus genes. In vitro, the expression of the BZLF1 gene is sufficient for the disruption of latency. The cellular mechanisms which control BZLF1 expression are unknown. Several cis-acting negative regulatory elements have been identified in the BZLF1 (PI) promoter. The hypothesis that cellular factors negatively regulate the transcription of the BZLF1 gene, function in a differentiation-dependent fashion and contribute to the regulation of latency will be tested. The long term objective is to achieve a better understanding of the regulation of EBV latency at the molecular level.
The specific aims of this proposal are: I. To purify, clone and identify the protein(s) which bind to more precisely mapped cis-acting negative sites in the BZLF1 promoter. Using DNA affinity chromatography, the factors which bind to the negative regulatory sequences will bc purified. These factors will be cloned from a phage library, sequenced and identified. II. To determine the effect or these proteins on BZLF1 promoter activity and EBV gene expression in latently infected cell lilies. The cDNA encoding the putative repressors will be cloned into plasmids containing heterologous promoters. The effect of these repressors on the BZLF1 promoter will be tested in transient cotransfection experiments; the effect on EBV replication will be tested by introducing plasmids containing either sense or antisense DNA under the control of a heterologous promoter and a selectable marker into latently infected EBV cell lines. After selection, cell lines containing either single or combinations of antisense RNA will be tested for virus expression. III.To assess the effect of virus inducing agents on the expression and function of these negative regulatory proteins. The effect of TPA, serum induction and anti-immunoglobulin on DNA binding, expression, and function of the repressor will bc assessed. IV.To determine whether there is a differentiation-dependent inverse correlation between repressor activity and virus replication. The CD phenotype of cell lines expressing antisense and sense repressor RNA will be determined. The expression levels of repressor in tumors previously characterized for virus expression and CD phenotype will be determined.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA058326-05
Application #
2429764
Study Section
Experimental Virology Study Section (EVR)
Program Officer
Wong, May
Project Start
1993-06-01
Project End
1999-05-31
Budget Start
1997-06-01
Budget End
1999-05-31
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Miscellaneous
Type
Other Domestic Higher Education
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Muntener, Michael; Epstein, Jonathan I; Hernandez, David J et al. (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767-75;discussion 775-6
Nielsen, Matthew E; Han, Misop; Mangold, Leslie et al. (2006) Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol 176:515-9
Nelson, W G; De Marzo, A M; DeWeese, T L (2001) The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology 57:39-45
Nelson, W G; De Marzo, A M; Deweese, T L et al. (2001) Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 952:135-44
Roberts, W W; Bergstralh, E J; Blute, M L et al. (2001) Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 57:1033-7
Han, M; Partin, A W; Pound, C R et al. (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-65
Feneley, M R; Partin, A W (2001) Indicators of pathologic stage of prostate cancer and their use in clinical practice. Urol Clin North Am 28:443-58
Han, M; Piantadosi, S; Zahurak, M L et al. (2001) Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57:707-11
Zhang, Q; Wang, Y C; Montalvo, E A (1999) Smubp-2 represses the Epstein-Barr virus lytic switch promoter. Virology 255:160-70
Pound, C R; Partin, A W; Eisenberger, M A et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-7

Showing the most recent 10 out of 14 publications